We are currently researching the programme and confirming the speakers for 2022.  The speakers list below relates to the 2021 Virtual London Summit.

We would like to thank all of our speakers who contribute their time and expertise to the Summit.


Deborah Arnott

Chief Executive

Action on Smoking and Health

Deborah Arnott is a recognised international expert on tobacco control and the WHO Framework Convention on Tobacco Control, with a particular interest in nicotine regulation and harm reduction. She was a member of the National Institute for Health and Care Excellence committee which developed guidance for England on tobacco harm reduction and of an expert advisory group to the UK’s medicines regulator the MHRA on e-cigarettes.  She also has experience of product regulation under the EU General Product Safety Directive having participated in the development of fire safety requirements for cigarettes. Deborah has an MBA from Cranfield, is an honorary Associate Professor at the University of Nottingham, and a member of the Royal College of Physicians Tobacco Advisory Group.  She was awarded the Alwyn Smith prize in 2007 by the Faculty of Public Health for her outstanding contribution to public health. Competing Interest: None Stated

Clive Bates


Counterfactual Consulting Ltd

Clive Bates has had a diverse career in the public, private and not-for-profit sectors.  He started out with the IT company, IBM, then switched career to work in the environment movement. From 1997-2003 he was Director of Action on Smoking and Health (UK), campaigning to reduce the harms caused by tobacco. In 2003 he joined Prime Minister Blair’s Strategy Unit as a civil servant and worked in senior roles in the public sector and for the United Nations in Sudan. He is now Director of Counterfactual, a consulting and advocacy practice focussed on a pragmatic approach to sustainability and public health.

Prof Linda Bauld, OBE

Bruce and John Usher Chair in Public Health in the Usher Institute

College of Medicine, University of Edinburgh

Professor Linda Bauld holds the Bruce and John Usher Chair in Public Health in the Usher Institute, College of Medicine at the University of Edinburgh. Linda is a behavioural scientist whose research focuses on two main areas: the evaluation of complex interventions to improve health, and how research can inform public health policy. She leads two research Consortia - the Tobacco Control Capacity Programme, involving research teams in five countries in Africa and three in South Asia - and SPECTRUM, involving 10 UK Universities and partner organisations conducting research on the commercial determinants of health. Over the years she has combined her academic roles with part time secondments to contribute to policy and practice. This includes, for example as: scientific adviser on tobacco control to the UK government (2006-2010); Cancer Research UK’s cancer prevention champion (2014-July 2021); adviser to the Covid-19 committee of the Scottish parliament (November 2020-April 2021); and currently as Chief Social Policy Adviser to the Scottish Government, with a focus on Covid recovery. She is a Fellow of the Royal College of Physicians of Edinburgh, the Academy of Social Sciences, the Royal Society of Edinburgh, and the Faculty of Public Health, and was awarded an OBE in the 2021 Queens Birthday Honours.

Prof Robert Beaglehole

Emeritus Professor

University of Auckland, New Zealand & Chair ASH - Action for Smokefree 2025, NZ

Robert Beaglehole is an independent public health physician with a longstanding interest in the prevention and management of chronic diseases. He was professor of public health at the University of Auckland before taking up a position at WHO, Geneva where he became the Director of the Department of Chronic Diseases and Health Promotion before returning to New Zealand. In 1982 he established ASH (NZ) and now Chairs the ASH Board.

Prof Alan Boobis, OBE

Emeritus Professor of Toxicology & Chair - UK Committee on Toxicity

Imperial College London

Alan Boobis is emeritus Professor of Toxicology, Imperial College London. He retired from his chair at the College in June 2017, after over 40 years.  His main research interests lie in mechanistic toxicology, mode of action and chemical risk assessment.  He has published over 250 original research papers (H-factor 80).  He is or has been a member of several national and international advisory committees; including current chair of the UK Committee on Toxicity, member of the WHO Study Group on Tobacco Product Regulation (TobReg), FAO/WHO JECFA (veterinary residues) and FAO/WHO JMPR (pesticide residues). He is a fellow of several learned societies and has received a number of awards, including Officer of the British Empire (OBE).

Hazel Cheeseman

Deputy Chief Executive & Policy Director

ASH (Action on Smoking & Health)

Hazel has worked across health and social care policy in the UK and abroad. She currently manages ASH’s policy development work. With a background in health and housing policy Hazel has particular expertise in local government and the delivery of policy at a local level. Hazel also co-ordinates two coalitions dedicated to addressing the health inequalities caused by smoking; The Smoking in Pregnancy Challenge Group and the Mental Health and Smoking Partnership.

Craig Copland

E-Cigarette Unit Manager - Vigilance and Risk Management of Medicines

MHRA - The Medicines and Healthcare products Regulatory Agency

Prior to employment at the MHRA, Craig Copland worked in the health food sector and fitness industry before taking up a position with the Portsmouth Trading Standards Service from 2007 to 2017.  In his capacity as a Trading Standards and Financial Intelligence Officer for Portsmouth City Council, Craig has worked across a broad spectrum of regulation, with a focus on business compliance, consumer protection and product safety. This work has also required Craig to lead and support numerous criminal investigations with a particular focus on vulnerable consumers and counterfeit and unsafe goods. Additionally, Craig developed a number of Primary Authority Partnerships, including work with E-cigarette importers and manufacturers under the pre and post TPD regulatory frameworks.  Since joining the agency Craig has overseen the MHRA competent authority responsibilities in operating the UK notification scheme, while continuing to develop links and work closely with regional and international agencies involved in E-cigarette regulation and enforcement, including the CTSI Tobacco Focus Group,  Joint Action on Tobacco Control Group, TPD Enforcement Group and EU Expert Panel on E-cigarettes. The last 18 months has also seen the development and successful launch of the MHRA GB submissions portal for E-cigarettes.

Andrea Crossfield MBE

Independent Public Health Consultant and Population Health Policy Specialist

Greater Manchester Health and Social Care Partnership

Andrea leads the Making Smoking History Strategy for Greater Manchester city region to reduce smoking prevalence further and faster than anywhere else in the UK and globally. With a career long commitment to tackling health inequalities, Andrea was previously CEO at Healthier Futures. She has extensive experience in local government and at director level in the NHS and VCSE sectors at local, regional and national levels.

Martin Dockrell

Tobacco Control Programme Lead

Office of Health Improvement & Disparities (OHID)

Martin is Tobacco Control Programme Lead for (OHID) The Office of Health Improvement and Disparities (previously Public Health England). He joined PHE in February after 7 years at Action on Smoking and Health. Martin has worked in Public Health since the mid 1980’s when he was involved in HIV prevention work. He is a fellow of the Royal Society of Public Health.

Cliff Douglas JD

Director, Tobacco Research Network, Adjunct Professor, Dep't of Health Management and Policy

University of Michigan School of Public Health

Cliff Douglas is the Director of the University of Michigan Tobacco Research Network, an adjunct professor at the School of Public Health, and a co-principal investigator for the Center for the Assessment of Tobacco Regulations at the University of Michigan. He was the American Cancer Society’s Vice President for Tobacco Control from 2015 to 2020, where he led the development of a comprehensive new public health approach to tobacco control, set forth in the American Cancer Society Public Health Statement on Ending Combustible Tobacco Use in the United States (2018), and co-founded the National Partnership on Behavioral Health and Tobacco Use, which is dedicated to increasing cessation and reducing mortality and illness in smokers with mental health conditions. He also provided expertise on issues related to the changing tobacco product marketplace and guided ACS’s efforts to educate the public about the impact of smoking on COVID-19. Previously, he served as a policy advisor for the Assistant Secretary for Health and the U.S. Surgeon General in the Obama administration, where he was a lead author of the Tobacco Control Strategic Action Plan for the U.S. Department of Health and Human Services. Earlier in his career, he coordinated the successful national campaign to make all commercial airline flights smoke-free and participated as an attorney and public health expert in the litigation that resulted in adoption of the Master Settlement Agreement. As special counsel for Congressman Martin Meehan and the Congressional Task Force on Tobacco and Health in the U.S. House of Representatives, he wrote legislation and prepared the 111-page prosecution memorandum that persuaded the U.S. Attorney General to launch a criminal investigation into the tobacco industry and later file the Justice Department’s landmark racketeering (RICO) action against the major tobacco companies. As told in Civil Warriors: The Legal Siege on the Tobacco Industry, Mr. Douglas also helped tobacco industry whistleblowers go public, and initiated an ABC News expose on the tobacco companies’ engineering of their products to cause dependency that led the Food and Drug Administration to open a two-year investigation and regulate tobacco for health and safety for the first time.

Dr Konstantinos Farsalinos M.D

External Research Associate

University of Patras, Department of Public and Community Health, University of West Attica, Greece

Konstantinos Farsalinos, MD, MPH is a cardiologist and research fellow at the Onassis Cardiac Surgery Center in Athens-Greece, at the Department of Pharmacy, University of Patras-Greece and at the National School of Public Health-Greece. He is specialized in echocardiography and in smoking and tobacco harm reduction research. He was the lead researcher in Intervendor Study, a joint research project of the European and American Societies of Echocardiography. He has been conducting laboratory, clinical and epidemiological research on smoking, tobacco harm reduction and e-cigarettes as principal investigator since 2011. As of 2019, he has published more than 70 studies and articles in international peer-reviewed scientific journals about smoking, tobacco harm reduction, and e-cigarettes. He was the handling editor and author in a book titled "Analytical assessment of e-cigarettes", published by Elsevier in 2017.

Prof Thomas J. Glynn, PhD

Adjunct Lecturer

Stanford Prevention Research Center, Stanford University School of Medicine

Dr. Glynn is, from 2014 to the present, Adjunct Lecturer, Stanford Prevention Research Center, Stanford University School of Medicine and Executive Team Member, Mayo Clinic Global Bridges Initiative. From 1998 to 2014, he was Director, Cancer Science and Trends and Director, International Cancer Control at the American Cancer Society (ACS). Prior to the ACS, Dr. Glynn was, from 1991 to 1994, Associate Director of the U.S. National Cancer Institute's (NCI) Cancer Control Science Program and, from 1991 to 1998, Chief of the NCI's Cancer Control Extramural Research Branch. From 1983 to 1991, he was Research Director for the NCI's Smoking, Tobacco, and Cancer Program and from 1978 to 1983, he was a Research Psychologist at the National Institute on Drug Abuse. Dr. Glynn has published widely on cancer and tobacco use prevention and control, both in the scientific literature and for consumer, professional, and patient education. In addition to his work at the ACS and NCI, he has served as a consultant on cancer control and tobacco issues to such groups as the National Academy of Sciences/Institute of Medicine, the National Research Council, the Robert Wood Johnson Foundation, the WHO, a variety of pharmaceutical organizations, and national, state and local governments. He has also served as a Senior Scientific Reviewer for the U.S. Surgeon General's Reports on Tobacco and Health, as Director of the World Health Organization Study of Health, Economic, and Policy Implications of Tobacco Growth and Consumption in Developing Countries, and has been active in tobacco control programs in Eastern Europe, Central America, and India. He is a Fellow of the Society for Research on Nicotine and Tobacco and his awards include the U.S. National Institutes of Health Merit Award, the Polish Ministry of Health Service Award, the Guatemala National Council for Tobacco Prevention and Control Meritorious Service Award, the Society for Research on Nicotine and Tobacco John Slade Award, and the American Society of Preventive Oncology Joseph W. Cullen Memorial Award.

Marc Gunther


Nonprofit Chronicles/Freelance

Marc Gunther is a veteran reporter who writes about many things, including philanthropy, tobacco policy, psychedelic drugs and animal rights. He took a critical look at the campaign against vaping funded by Bloomberg Philanthropies in a long story in the Chronicle of Philanthropy last March. His writing about e-cigarettes and tobacco can be found here. Marc was a senior writer at FORTUNE magazine and editor at large of Guardian Sustainable Business US. He has contributed stories to The New York Times, Washington Post, Vox and Mother Jones. A graduate of Yale University, he lives in Bethesda, Maryland.

Prof Peter Hajek

Professor of Clinical Psychology

Wolfson Institute of Public Health, Queen Mary University of London

Peter Hajek is Professor of Clinical Psychology and Director of the Tobacco Dependence Research Unit at the Wolfson Institute of Preventive Medicine, Queen Mary University of London. His research is concerned primarily with understanding health behaviours, and developing and evaluating both behavioural and pharmacological treatments for dependent smokers and for people with weight problems. Professor Hajek is a member of a number of expert groups, advisory bodies and editorial boards, and has authored or co-authored over 350 publications.

Prof Wayne Hall

Professor Emeritus, National Centre for Youth Substance Use Research

The University of Queensland

Wayne Hall is an Emeritus Professor at the National Centre for Youth Substance Use Research at the University of Queensland and the Queensland Alliance for Environmental Health Sciences. He was: a Professor at the National Addiction Centre, Kings College London (2014-2019) and a Visiting Professor at the London School of Hygiene and Tropical Medicine (2012-2021). He has advised the World Health Organization on the health effects of cannabis use; the effectiveness of drug substitution treatment; the contribution of illicit drug use to the global burden of disease; and the ethical implications of genetic and neuroscience research on addiction.

Dr Jamie Hartmann-Boyce

Managing Editor, Cochrane Tobacco Addiction Group & Senior Research Fellow

University of Oxford

Jamie Hartmann-Boyce is a senior research fellow and departmental lecturer with the Centre for Evidence-Based Medicine at the Nuffield Department of Primary Care Health Sciences, University of Oxford. Her particular interests lie in evidence synthesis (both quantitative and qualitative) and the communication of complex information and data to inform policy and public action. Her research mainly consists of complex evidence synthesis work. She leads the Cochrane review of electronic cigarettes for smoking cessation, which is now a living review funded by Cancer Research UK, updated monthly, and is an editor for the Cochrane Tobacco Addiction Group.  

Prof Martin Jarvis

Emeritus Professor of Health Psychology, Department of Behavioural Science & Health

University College London

Martin Jarvis is Emeritus Professor of Health Psychology at the Department of Behavioural Science & Health, University College London. He has been researching tobacco and nicotine use for the past 40 years. He has served as a trustee of ASH, was Chair of the UK government’s Technical Advisory Group on Tobacco and Health, and was Specialist Adviser to the House of Commons Health Committee’s inquiries into tobacco and health and into smoking in public places.  He was for some years a member of the World Health Organisation’s study group on Tobacco Product Regulation. With colleagues Robert West and Jamie Brown he has recently published a paper on the youth vaping “epidemic” in the USA : Jarvis MJ, West R, Brown J. Epidemic of youth nicotine addiction? What does the National Youth Tobacco Survey reveal about high school e-cigarette use in the USA?

Prof Daniel Kotz

Professor in addiction research and clinical epidemiology, Institute of General Practice

Centre for Health and Society, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Germany

Prof. Dr. Daniel Kotz is professor in addiction research and clinical epidemiology at the Institute of General Practice, Centre for Health and Society, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Germany. He also holds research affiliations with Maastricht University, University College London, and the University of Edinburgh. He was trained as a health scientist and epidemiologist. His main areas of research are tobacco addiction (use of tobacco and alternative nicotine delivery systems in populations, effectiveness and safety of behavioural and pharmacological treatments in clinical care), chronic obstructive pulmonary disease (prediction modelling, early detection, prevention) and clinical epidemiology (research methodology and reporting). He has published over 150 scientific articles in international peer-reviewed journals (H-Index = 27), including leading journals in the categories general medicine (Lancet, JAMA Internal Medicine), respiratory medicine (Lancet Respiratory Medicine, Thorax, Chest, European Respiratory Journal), and substance abuse/public health (Addiction, Tobacco Control). He is Senior Editor of Addiction, Editorial Board member of the Journal of Clinical Epidemiology, former President of the Society for Research on Nicotine and Tobacco (SRNT) Europe, and member of the International Primary Care Research Leadership Programme. More information: www.daniel-kotz.de

Prof David Levy

Professor of Oncology

Lombardl Comprehensive Cancer Center, Georgetown University

David Levy has a PhD in Economics from UCLA and is currently a Professor of Oncology at Georgetown. He has published over 200 papers, including articles in the American Economic Review, American Journal of Public Health, JAMA, Lancet, Medical Care, American Journal of Preventive Medicine, Obesity Review, Tobacco Control, and the Review of Economics and Statistics. His work spans topics in public health and industry behavior.  Dr. Levy has been principal investigator of grants from the Centers for Disease Control and Prevention, the World Health Organization, the National Cancer Institute, the National Institute on Drug Abuse, Bloomberg/Gates Foundation, European Union, and the Robert Wood Johnson Foundation.  He is currently the principal investigator of an FDA TCORS, and grants from the National Cancer Institute to the ITC project and to the CISNET Lung group.  Dr. Levy oversees the design and development of the SimSmoke tobacco policy simulation model, which predicts the effect of tobacco policies, such as tax increases, smoke-free air laws, media campaigns, youth access policies, and cessation treatment policies, on smoking rates and tobacco-related deaths. He has developed models for 10 states and for over 60 countries. He is currently developing simulation models that incorporate the use of smokeless tobacco and e-cigarettes.

Paul Lincoln OBE

Chair - Tobacco: preventing uptake, promoting quitting and treating tobacco dependence

(NICE) National Institute of Clinical and Health Excellence -

Paul Lincoln has worked In public health at local, national and international levels in the public and third sector. For 40 years. He is currently the Chair of one of the National Institute of Clinical and Health Excellence standing Public Health Advisory Committees and Chairs the Diabetes guidelines committee. He also chairs the alcohol advisory group for PHE and its successor organisation. He is involved with research investigations on trade and health and is a strategic adviser to many national charities. Previously he was Chief Executive of the UK Health Forum and a Director of the Health Education Authority and a Chair and member of numerous Government and scientific expert public health advisory groups He was awarded an OBE in the 2008 New Year honours list for services to healthcare and is an honorary fellow/member of the Royal College of Physicians, the Association of Directors of Public Health, Faculty of Public Health and a Professorial Fellow to the Royal Society of Public Health. He is also a visiting Professor at Chester University

Dr Karl E. Lund

Senior Researcher

Norwegian Institute of Public Health

Dr. Karl E. Lund is senior researcher at the Norwegian Institute of Public Health. He was Research Director at the Norwegian Institute for Alcohol and Drug Research for the period 2006-2018. He has been involved in tobacco control work since the mid-1980s, and received the Norwegian Medical Association’s Award in preventive medicine in 2000. Dr. Lund has been a member of several expert committees including WHO’s International Agency for Cancer Research (IARC). He is Associate Editor in Nicotine & Tobacco Research and a Senior Associate Editor of Tobacco Regulatory Science. He has been an expert witness in several lawsuits against the tobacco industry. Dr. Lund holds a Ph.D. in Sociology from 1996 and he was formally assessed with qualifications as Professor in 2009.

Prof Ann McNeill

Professor of Tobacco Addiction

Institute of Psychiatry, Psychology & Neuroscience,, Kings College London

Ann McNeill is a Professor of Addictions in the National Addiction Centre with a focus on tobacco. She graduated from the University of Nottingham with a first class joint honours degree in zoology and psychology and then carried out her PhD at the Institute of Psychiatry focusing on the development of dependence on smoking. Since that time she has held a variety of academic and public sector posts focusing largely on tobacco control research. Ann has an established international reputation, receiving a World Health Organisation award for contributions to tobacco control in 1998. She has published more than 250 academic papers book chapters, reports and opinion pieces on the subject and her research ranges across prevention, cessation, harm reduction and local, national and international policy. Ann was a co-author of the recent systematic review of tobacco product packaging which underpinned the recent government consultation on plain packaging and has a particular interest in the relationship between smoking, mental health and inequalities. She is Deputy Director of the UK Centre for Tobacco Control Studies. Competing Interest: Professor McNeill leads the Nicotine Research Group in the Addictions Department, IoPPN and receives funding for projects from a variety of funders such as Cancer Research UK (CRUK) and the National Institute for Health Research (NIHR) and has no links with any tobacco or vaping product manufacturers. Professor McNeill is a NIHR Senior Investigator

Dr Colin Mendelsohn MB BS (Hons)

General practitioner, Founding Chairman

Australian Tobacco Harm Reduction Association

Colin was a GP in Sydney, Australia for 27 years with a special interest in smoking cessation and now works exclusively in tobacco treatment. He is a member of the committee that develops the Australian RACGP national smoking cessation guidelines and is the Founding Chairman of the Australian Tobacco Harm Reduction Association. Colin was a Conjoint Associate Professor in the School of Public Health and Community Medicine at the University of New South Wales, Sydney, and is the author of a new book, Stop Smoking Start Vaping, an evidence-based self-help guide to vaping. Apart from his clinical and university work, Colin has conducted hundreds of workshops and lectures around Australia and New Zealand teaching students, medical practitioners and other health professionals how to help smokers quit. For many years he was actively involved in researching, developing and teaching Smokescreen for the 1990s, a program developed at the University of New South Wales for use by general practitioners to help smokers quit Disclosure I have no financial or commercial relationship with any electronic cigarette or tobacco company. Never have, never will. I provide advice to the pharmaceutical industry and other organisations that require specialist advice in the field of smoking cessation. I have received payments for teaching, consulting and conference expenses from Pfizer Australia, GlaxoSmithKline, Johnson & Johnson Pacific and Perrigo Australia.  

Prof Robin Mermelstein

Distinguished Professor of Psychology & Director, Institute for Health Research and Policy

University of Illinois, Chicago

Dr. Robin Mermelstein, a Distinguished Professor, College of Liberal Arts and Science, Department of Psychology, directs the Institute for Health Research and Policy at the University of Illinois at Chicago. She also is a research professor of community health sciences in the UIC School of Public Health, and the co-director of the UIC Center for Clinical and Translational Science. Her research interests fall broadly in the area of tobacco use, with studies ranging from longitudinal examinations of the etiology of youth smoking to cessation interventions for adult smokers. Since the mid 1990s, Dr. Mermelstein has been the principal investigator of a series of studies, including two consecutive program projects funded by the National Cancer Institute, to investigate trajectories of smoking patterns among adolescents and young adults, with a focus on social and emotional contextual factors. In addition, she has been funded by the Centers for Disease Control and Prevention to examine factors related to youth smoking, and by the National Heart, Lung, and Blood Institute, the National Institute on Drug Abuse, and the National Cancer Institute for studies of adult smoking reduction and cessation. Other areas of research focus include health behaviors of young adults and motivational interventions to increase smoking cessation. Dr. Mermelstein is the past-president of the Society for Research on Nicotine and Tobacco and serves on national research review committees of the National Institutes of Health. She served on the Institute of Medicine committee that wrote the 2015 consensus study report, Public Health Implications of Raising the Minimum Age of Legal Access to Tobacco Products. She directed the Robert Wood Johnson Foundation's national program office of Partners with Tobacco Use Research Centers: A Transdisciplinary Approach to Advancing Science and Policy Studies. As part of this program, RWJF collaborated with both NCI and the National Institute on Drug Abuse in funding the Transdisciplinary Tobacco Use Research Centers. In 2014, the University of Illinois at Chicago named Dr. Mermelstein Woman of the Year for her contributions to women's health and professional development.

Professor Marcus Munafò

Professor of Biological Psychology and MRC Investigator

School of Psychological Science, University of Bristol

Marcus Munafò is Professor of Biological Psychology in the School of Psychological Science, and MRC Investigator in the MRC Integrative Epidemiology Unit, at the University of Bristol. His research interests include the understanding causal pathways between health behaviours and physical and mental health. He also has a long-standing interest in the factors that influence research quality, and in 2019 co-founded the UK Reproducibility Network (www.ukrn.org; @ukrepro).

Prof Caitlin Notley

Chair of Addiction Sciences

University of East Anglia

Caitlin Notley is a social scientist, with extensive experience running qualitative studies as stand alone projects, to develop interventions, or alongside clinical trials. Her particular areas of research expertise are tobacco smoking cessation, relapse prevention and trajectories of electronic cigarette use. Professor Notley leads the Addiction Research Group at the University of East Anglia, and is Director of the Faculty of Medicine and Health ‘Citizen’s Academy’. She is an experienced Cochrane review author, as a member of the Tobacco Addiction Group, and an Associate Editor for the journals Addiction and Nicotine and Tobacco research. Currently, Professor Notley is leading two large NIHR funded randomised controlled trials evaluating a relapse prevention intervention and smoking cessation support, including the offer of a vape starter kit, for patients attending hospital emergency departments.

Rosanna O’Connor

Director, Addictions & Inclusion

Office for Health Improvement & Disparities, Department of Health and Social Care

Rosanna O’Connor has been appointed as the Director of Addictions & Inclusion in the new Office of Health Improvement & Disparities, following her interim role as director of Public Health England’s (PHE) Health Improvement Directorate, during the pandemic and PHE’s Transition. Rosanna’s new role covers alcohol, drugs, tobacco, and gambling, plus the inclusion health agendas of homelessness & rough sleeping, migrant health, sex workers and GRT. In PHE since 2013, Rosanna was the director for alcohol, drugs, tobacco & justice, with many successes under her belt, including PHE’s e-cigarette reports and the introduction of plain packs, and was always interested in how policies and delivery could reduce health inequalities. Prior to PHE’s establishment Rosanna was Director of Delivery at the National Treatment Agency for substance misuse with responsibility for all drugs policy development, performance management and support to community providers and commissioners and to prisons. Rosanna’s earlier career was in the third sector with social care and specialist housing providers and has a significant track record of challenging the impact of disadvantage on individuals, families, and communities.

Dr Michael Pesko

Health Economist & Associate Professor

Department of Economics, Andrew Young School of Policy Studies, Georgia State University

Michael Pesko is a health economist and an Associate Professor in the Department of Economics at Georgia State University. Dr. Pesko uses natural experiments from e-cigarette policy changes to study benefits and drawbacks of allowing the sale of e-cigarettes as consumer products. He has received funding from the National Institute on Drug Abuse, National Cancer Institute, and the American Cancer Society. He is also a co-organizer of the Tobacco Online Policy Seminar (www.tobaccopolicy.org).

Tim Phillips

Managing Director


The founder and managing director of ECigIntelligence, Tim is a UK-qualified attorney, having worked at the European Commission, BSkyB and Herbert Smith (an international law firm), AOL Europe, as director of public affairs at Betfair (IPO in 2010 valued at £1.5bn), and as a partner in a New York VC-funded start-up in the diamond sector. Tim holds a Postgraduate Diploma in Legal Practice from the University of Law, London and a Masters in Geology from Oxford University.

Kate Pike

Co-ordinator - Trading Standards North West

Member of the Department of Health and Social Care National Tobacco Focus Group

Kate is Co-ordinator for Trading Standards North West and a member of the Department of Health and Social Care National Tobacco Focus Group. She is an experienced sales and marketing professional, having worked for many years in multinational businesses in the private sector, responsible for building and maintaining excellent customer relationships across the world. She brought her project management and customer relationship skills to the public sector in 2007 and is responsible for co-ordinating activity and facilitating strategic development across the 23 Local Authority Trading Standards Services in the North West

Dr Debbie Robson RMN, PhD

Senior Lecturer in Tobacco Harm Reduction

National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London

Debbie’s work focuses on the development and evaluation of tobacco harm reduction strategies, including e-cigarettes, in mental health and substance use settings.  She is a co-author of Public Health England commissioned annual evidence reviews of e-cigarettes and is a Trustee of Action on Smoking and Health (ASH).

Louise Ross

Interim Chair and Mental Health Lead for the New Nicotine Alliance

Business Development Manager - Smoke Free - Quit Smoking Now

Louise Ross retired in 2018 as the manager of the Leicester, England, Stop Smoking Service, but continues to be active in tobacco harm reduction. The Leicester stop smoking service was the first in the country to go ‘ecig-friendly’ on No Smoking Day 2014. She now works as Business Development Manager for the Smoke-Free app Smoke Free – Quit Smoking Now which includes managing the expert team of advisors who offer live on-demand support to smokers who want to quit, whether this is with traditional products, vaping, novel nicotine products or no products at all. She also works as a freelance consultant for the National Centre for Smoking Cessation and Training NCSCT – National Centre for Smoking Cessation and Training where many tobacco harm reduction resources can be found (see the NCSCT YouTube channel) Louise is the Vice-Chair and Mental Health Lead for the New Nicotine Alliance Home – New Nicotine Alliance UK

Marcus Saxton


Independent British Vape Trade Association (IBVTA)

Marcus Saxton is the Chief Executive of the ‘Totally Wicked Group’ and Chairman of the Independent British Vape Trade Association (IBVTA).  Founded in 2016, the IBVTA is a not-for-profit, non-political trade association, which exists to provide credible knowledge and guidance to support the independent vape sector and promote constructive interaction between this industry sector and the scientific community, vapers, regulators, policy makers, and the general public. Prior to joining the sector, and specifically Totally Wicked Marcus spent over 20 years’ within a variety of leadership roles for many household FMCG businesses; PZ Cussons Plc, Molson Coors Beer Company, GlaxoSmithkline, Britvic Soft Drinks and Mars UK.

Prof Lion Shahab

Professor of Health Psychology

Department of Behavioural Science and Health, University College London

Dr Shahab is Professor of Health Psychology at University College London and past President for the Society for Research on Nicotine and Tobacco – Europe. He trained in psychology, epidemiology and neuroscience and has more than 17 years’ experience in addiction research, tobacco control and health psychology. Dr Shahab’s expertise spans work on novel behavioural and pharmacological smoking cessation interventions, biomarkers, tobacco product regulation and policy, digital health and tobacco and alcohol use epidemiology. Dr Shahab has collaborated with academic as well as non-academic (e.g. governmental and non-governmental) partners and to date has authored over 140 scientific papers, reports and reviews in this area.

Professor Robert West

Professor Emeritus of Health Psychology

University College London

Robert West is Professor Emeritus of Health Psychology at University College London, UK.  He is Editor-in-Chief of the journal Addiction. He specialises in addiction and behaviour change and has authored or co-authored more than 900 scientific works including several books: Energise: The Secrets of Motivation, Theory of Addiction, Models of Addiction, The SmokeFree Formula, and The Behaviour Change Wheel. His personal website is www.rjwest.co.uk. Twitter: @robertjwest. He has undertaken research and consultancy for companies that develop and manufacture smoking cessation medications but not e-cigarettes. He is an unpaid advisor to the UK’s National Centre for Smoking Cessation and Training. Most of his research is funded by Cancer Research UK.